Acceleron Pharma Inc (XLRN) Expected to Post Quarterly Sales of $3.39 Million
Wall Street brokerages expect Acceleron Pharma Inc (NASDAQ:XLRN) to announce $3.39 million in sales for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Acceleron Pharma’s earnings, with estimates ranging from $2.76 million to $4.50 million. Acceleron Pharma posted sales of $3.37 million in the same quarter last year, which suggests a positive year-over-year growth rate of 0.6%. The company is expected to issue its next quarterly earnings report on Wednesday, March 7th.
According to Zacks, analysts expect that Acceleron Pharma will report full-year sales of $3.39 million for the current financial year, with estimates ranging from $12.54 million to $14.27 million. For the next year, analysts expect that the company will report sales of $27.28 million per share, with estimates ranging from $13.20 million to $37.00 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Acceleron Pharma.
Several research analysts recently weighed in on the stock. Credit Suisse Group reissued an “outperform” rating and issued a $55.00 target price on shares of Acceleron Pharma in a research note on Thursday, January 18th. BidaskClub raised shares of Acceleron Pharma from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. Cann reissued a “hold” rating on shares of Acceleron Pharma in a research note on Monday, January 8th. Oppenheimer reissued a “hold” rating on shares of Acceleron Pharma in a research note on Monday, January 8th. Finally, Royal Bank of Canada reissued a “hold” rating on shares of Acceleron Pharma in a research note on Thursday, November 2nd. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $44.81.
In related news, SVP Christopher Rovaldi sold 2,266 shares of the stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $42.42, for a total transaction of $96,123.72. Following the completion of the sale, the senior vice president now owns 52,977 shares of the company’s stock, valued at approximately $2,247,284.34. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Kevin F. Mclaughlin sold 4,000 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $42.42, for a total transaction of $169,680.00. Following the sale, the chief financial officer now directly owns 45,300 shares of the company’s stock, valued at approximately $1,921,626. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 146,021 shares of company stock valued at $5,529,598. Corporate insiders own 3.90% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Quantbot Technologies LP increased its position in Acceleron Pharma by 416.3% during the 3rd quarter. Quantbot Technologies LP now owns 2,917 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 2,352 shares in the last quarter. Public Employees Retirement Association of Colorado acquired a new stake in Acceleron Pharma during the 4th quarter worth approximately $138,000. Oppenheimer & Co. Inc. acquired a new stake in Acceleron Pharma during the 3rd quarter worth approximately $225,000. Trexquant Investment LP acquired a new stake in Acceleron Pharma during the 3rd quarter worth approximately $266,000. Finally, Bailard Inc. acquired a new stake in Acceleron Pharma during the 4th quarter worth approximately $340,000. 85.56% of the stock is owned by hedge funds and other institutional investors.
About Acceleron Pharma
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.